The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Taiho Pharmaceutical
Leadership - Taiho Pharmaceutical
Travel, Accommodations, Expenses - Taiho Pharmaceutical
TAGS, a randomized, double-blind, phase 3 study evaluating TAS-102 plus best supportive care vs placebo plus best supportive care in patients with metastatic gastric cancer refractory to standard treatments.
 
David H. Ilson
Consulting or Advisory Role - Amgen; Lilly/ImClone; Roche/Genentech
Speakers' Bureau - Genentech/Roche
Research Funding - Amgen; Bayer; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Amgen; Genentech/Roche
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck; Merck Serono; Millennium; Novartis; Roche/Genentech; Sanofi; Symphony Evolution; Taiho Pharmaceutical
 
Kohei Shitara
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Novartis; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bayer (Inst); Chugai Pharma (Inst); Lilly (Inst); Takeda (Inst)
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Robert Winkler
No Relationships to Disclose
 
Ali Nasermoaddeli
Employment - Taiho Pharmaceutical
Stock and Other Ownership Interests - Otsuka
 
Cliff Ding
Employment - Taiho Pharmaceutical
 
Toshihiko Doi
Consulting or Advisory Role - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; Nippon Boehringer Ingelheim; Novartis; Otsuka
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sanofi (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)